Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Tysabri, the MS Drug Haunted by Deadly Side Effect, Doesn’t Look So Deadly Anymore
|
Luke Timmerman |
11/19/09 |
Boston
|
|
Biogen Shares Drop as Tysabri PML Cases Climb to 23, Europe May Seek Drug ‘Holiday’
|
Luke Timmerman |
10/23/09 |
Boston
|
|
Tysabri’s Tally of PML Cases Reaches 13
|
Luke Timmerman |
09/17/09 |
Boston
|
|
Biogen Gets Int’l Rights to Acorda’s MS Drug
|
Roxanne Palmer |
07/01/09 |
Boston
|
|
Biogen Reports 10th PML Case in Tysabri Patient
|
Roxanne Palmer |
06/29/09 |
Boston
|
|
Biogen Idec To Show Off MS Drugs at Seattle Neurology Meeting
|
Luke Timmerman |
04/24/09 |
Boston
|
|
Tysabri Patient Dies of Brain Infection, First Death Since Drug Re-Introduced
|
Luke Timmerman |
12/19/08 |
Boston
|
|
Tysabri Patient Diagnosed With PML
|
Luke Timmerman |
12/15/08 |
Boston
|
|
Tysabri: The Big Multiple Sclerosis Drug That Emerged From “The Hutch”
|
Luke Timmerman |
11/04/08 |
Seattle
|
|
Biogen Idec, Elan’s Tysabri Linked to First U.S. Case of Brain Infection
|
Luke Timmerman |
10/29/08 |
Boston
|
|
Biogen Turns Down Dying Patient’s Request For Tysabri—and Explains Why
|
Luke Timmerman |
10/14/08 |
Boston
|
|
Biogen Idec, Elan Start First Cancer Trial With Tysabri
|
Luke Timmerman |
09/05/08 |
Boston
|
|
FDA Doesn’t Appear Overly Alarmed by Recent Cases of Brain Disease Associated With Tysabri; Working with Biogen Idec and Elan to Update Labeling
|
Luke Timmerman |
08/26/08 |
Boston
|
|
Taligen CEO Aims to Develop Drugs For Inflammatory Diseases, Build Company in Cambridge
|
Luke Timmerman |
08/14/08 |
Boston
|
|
Icahn Ups Biogen Idec Stake to 6 Percent—Bought Big on Tysabri Woes
|
Ryan McBride |
08/12/08 |
Boston
|
|
Biogen Idec, Elan Shares Plummet on News of Two PML Cases With Tysabri
|
Luke Timmerman |
08/01/08 |
Boston
|
|
Biogen Idec, Elan Report Two New Cases of Rare Brain Infection in Tysabri Patients
|
Luke Timmerman |
07/31/08 |
Boston
|
|
Biogen Idec, Elan Say More Than 31,800 Patients Taking Tysabri For MS
|
Luke Timmerman |
07/22/08 |
Boston
|
|
Genzyme Reaching For a Slice From Biogen’s Breadbasket, Multiple Sclerosis Drugs
|
Luke Timmerman |
07/17/08 |
Boston
|
|
Page 1 of
1 |
|
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
